Developer docs
API playgroundTry for free, no card

Search company profiles

SciGen Korea Ltd.

Full company profile

uuid0059vvt

Namestring
SciGen Korea Ltd.
Legal namestring
SciGen Pte. Ltd.
Websiteurl
scigen.co.kr
Company typeenum
Private
Founded yearstring
-
Descriptiontext

SciGen Korea Ltd. is a South Korea-based biopharmaceutical subsidiary of Singapore-incorporated SciGen Pte. Ltd., employing approximately 12 people. The company markets and commercializes an integrated portfolio of healthcare products organized across three segments: Brand Drugs, Generics/Biosimilars, and Medical Devices. Its proprietary assets include Lorelin (the first GnRHa developed in Korea with an international patent), SciXeg (a pegfilgrastim biosimilar approved by both the FDA and EMA), SciLocyte (the first Filgrastim in pre-filled syringe format), SciTropin A (a European-quality recombinant human growth hormone in ready-to-use format), and the LTU-904 low-level laser treatment device for post-mastectomy lymphoedema. The portfolio also extends to in-licensed or distributed products such as Zometa, Diphereline, Gensulin/SciLin, ISCADOR, HERI, Zinc-S, and NeoTrace 4, spanning oncology, endocrinology, hematology, and supportive care.

SciGen operates a sales-led go-to-market built on out-licensing, partner due diligence, market analysis, and distribution agreements with manufacturers and channel partners. Products are commercialized across 12+ Asia-Pacific and emerging markets including South Korea, Philippines, Australia, Singapore, Malaysia, Vietnam, Hong Kong, Thailand, Taiwan, Indonesia, Brunei, and New Zealand. Revenue is generated through pharmaceutical product sales and licensing/distribution arrangements, with quote-based pricing through healthcare providers and distributors rather than disclosed list pricing. The customer base is described as healthcare providers and patients globally, with no named anchor customers or segment-level revenue disclosure.

The company is privately held with no disclosed funding rounds, institutional investors, or public listing. Its operating structure is lean relative to its geographic footprint, with a small team executing commercialization rather than in-house drug discovery. Strategic emphasis is on continuous portfolio fill and improvement across the three product categories, leveraging international regulatory approvals as a primary differentiation lever.

Short descriptiontext

SciGen Korea Ltd. is a Seoul-based biopharmaceutical subsidiary of Singapore's SciGen Pte. Ltd. that markets and commercializes brand drugs, generics/biosimilars, and medical devices across 12+ Asia-Pacific and emerging markets, serving healthcare providers and patients in oncology, endocrinology, and supportive care.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical products, generic pharmaceuticals, biosimilars distribution, medical devices marketing, oncology supportive care
Industry5 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Surgical and Medical Instrument Manufacturing339112
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code4 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Biopharmaceutical Commercialization
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

SciGen generates revenue through the marketing and commercialization of innovative healthcare products including brand drugs, generics, biosimilars, and medical devices. The company markets products worldwide across multiple countries including South Korea, Philippines, Australia, Singapore, Malaysia, Vietnam, Hong Kong, Thailand, Taiwan, Indonesia, Brunei, and New Zealand.

scigen.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SciXeg
Description

Biosimilar of pegfilgrastim approved by both the FDA and EMA for oncology and hematology supportive care.

scigen.com
+2 more records
Core offering1 text field

SciGen Korea markets and commercializes an integrated biopharmaceutical portfolio across Brand Drugs, Generics/Biosimilars, and Medical Devices for oncology supportive care, endocrinology, hematology, and immunology. The company distributes proprietary products such as Lorelin (GnRHa) and SciXeg (pegfilgrastim biosimilar), along with partnered brands like Zometa, Diphereline, Gensulin, and the LTU-904 laser device, through partner manufacturers and distributors across South Korea and other international markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SciGen is a biopharmaceutical company that markets and commercializes an integrated portfolio of innovative healthcare products organized across three main segments: Brand Drugs, Generics/Biosimilars, and Medical Devices. The company's product portfolio includes injectable pharmaceuticals (SciXeg® biosimilar, SciLocyte™, HERI®, Zometa®, Diphereline®, SciTropin A™, Gensulin®/SciLin™), oncology supportive care products (ISCADOR®, Zinc-S®, NeoTrace 4®), medical devices (LTU-904 laser treatment, Gensupen 2® insulin delivery device), and hormonal therapies (Lorelin). The products span therapeutic areas including endocrinology, oncology, hematology, and supportive care, with distribution across South Korea, Australia, Southeast Asia, and emerging markets worldwide.

Product and service13 records
1Lorelin
CategoryBrand Drug (GnRHa)
Description

Lorelin is the first GnRHa (Gonadotropin-Releasing Hormone agonist) developed in Korea with international patent approval. It is used for endocrinology, oncology, and OBGY indications, currently marketed in South Korea.

2SciXeg® (pegfilgrastim biosimilar 6mg)
CategoryBiosimilar (oncology/hematology supportive care)
Description

SciXeg is a G-CSF (granulocyte colony-stimulating factor) biosimilar of pegfilgrastim supplied as a 6mg pre-filled syringe injection, approved by both the FDA and EMA, and used for oncology and hematology supportive care. Marketed in South Korea.

3LTU-904
CategoryMedical Device (laser therapy)
Description

LTU-904 is an innovative low-level laser treatment medical device for patients suffering from Post-Mastectomy Lymphoedema. Marketed in South Korea.

4Gensupen 2®
CategoryMedical Device (insulin delivery)
Description

Gensupen 2 is an insulin delivery medical device used with injectable pharmaceutical products, distributed in emerging markets and used by thousands of patients worldwide.

5Zinc-S®
CategoryBrand Drug (zinc supplement / oncology supportive care)
Description

Zinc-S is a zinc sulfate hydrate pharmaceutical product for the prevention of low zinc levels, used in oncology applications. Marketed in South Korea.

6NeoTrace 4®
CategoryBrand Drug (parenteral trace elements / oncology)
Description

NeoTrace 4 is a sterile, nonpyrogenic solution of zinc, copper, manganese, and chromium used to prevent depletion of endogenous trace element stores and subsequent deficiency symptoms. Marketed in South Korea for oncology.

7ISCADOR®
CategoryBrand Drug (oncology supportive care)
Description

ISCADOR is a Swiss-made mistletoe (Viscum album) extract product addressing oncology support needs. Marketed in South Korea.

8HERI®
CategoryBrand Drug (immune modulator)
Description

HERI is an immune modulator containing Thymosin α1 designed to boost immune defense in immunocompromised patients. Marketed in South Korea.

9SciLocyte™ (Filgrastim in pre-filled syringe)
CategoryBrand Drug / Biosimilar (G-CSF oncology support)
Description

SciLocyte is the first Filgrastim in pre-filled syringe (PFS) format, a G-CSF product for increasing Absolute Neutrophil Count (ANC) with proven efficacy and safety. Currently marketed in the Philippines.

10Zometa® (zoledronic acid)
CategoryBrand Drug (bone / oncology supportive care)
Description

Zometa is a ready-to-use zoledronic acid formulation for bone-related conditions, marketed in Australia, Brunei, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.

11Diphereline®
CategoryBrand Drug (GnRH agonist / endocrinology)
Description

Diphereline is a prolonged-acting GnRH agonist with proven efficacy and safety data since 1986, used in endocrinology applications.

12SciTropin A™ (recombinant human growth hormone)
CategoryBrand Drug (rhGH / endocrinology)
Description

SciTropin A is a European quality recombinant human growth hormone (rhGH) supplied in a ready-to-use format for short stature correction. Currently marketed in Australia, Philippines, South Korea, Singapore, Vietnam, Malaysia, Hong Kong, and Thailand.

13Gensulin® / SciLin™ (recombinant human insulin)
CategoryBrand Drug (recombinant human insulin / diabetes)
Description

Gensulin (also marketed as SciLin) is a high-quality European recombinant human insulin with 20 years of experience confirming effectiveness, safety, and stability. Available in multiple formulations including Scilin N, Scilin R, and Scilin M30, distributed in emerging markets.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Potential Manufacturers and Distributors (unnamed)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

SciGen partners with manufacturers and distributors across different markets to represent their products. The partnership involves reaching out to potential partners, conducting partner due diligence, market analysis, product finalization, and agreement negotiation and finalization.

scigen.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

South Korea's leading biosimilar developer and manufacturer, with FDA/EMA approved pegfilgrastim and filgrastim biosimilars that directly compete with SciXeg and SciLocyte. Directly comparable in product category, regulatory strategy, and APAC commercial reach.

TypeDirect peer
Description

Iceland-based pure-play biosimilar developer with FDA/EMA approvals across oncology and immunology, actively expanding APAC distribution partnerships. Comparable as a biosimilar-focused company pursuing multi-territory regulatory commercialization.

TypeBroad incumbent
Description

India-headquartered specialty pharmaceutical company with branded specialty, biosimilars, and complex generics across global markets including APAC and emerging regions. Comparable via specialty pharma breadth and partner distribution emphasis.

TypeDirect peer
Description

Korean biosimilar specialist developing and commercializing multiple oncology and immunology biosimilars with FDA/EMA approvals. Directly comparable as a Korean-headquartered biosimilar player with global regulatory reach.

TypeBroad incumbent
Description

India's largest specialty pharmaceutical company with proprietary products, biosimilars (including G-CSF franchise), and significant APAC and emerging-markets presence. Comparable via biosimilar G-CSF overlap and broad specialty pharma portfolio.

TypeBroad incumbent
Description

India-based global pharmaceutical company with deep presence in oncology, respiratory, and specialty segments across APAC and emerging markets, including biosimilar and branded specialty franchises. Comparable as a large incumbent with overlapping therapeutic-area breadth and emerging-markets focus.

TypeDirect peer
Description

India-based specialty generics and biosimilar manufacturer with global footprint via Accurex and other channels, active in oncology and immunology biosimilars. Comparable in product mix and multi-territory partner-driven commercialization.

TypeDirect peer
Description

German specialty generics and biosimilar manufacturer with broad European specialty footprint and growing APAC presence. Comparable as a multi-territory specialty/generics player with in-licensing and partner distribution focus.

9LG Chem Life Sciences
TypeBroad incumbent
Description

Korean diversified chemical and life sciences business with growing specialty pharma and biosimilar investments, including growth hormone and oncology supportive care franchises. Comparable as a Korean specialty player expanding APAC and global biosimilar franchises.

TypeDirect peer
Description

India-headquartered developer of biosimilars (pegfilgrastim, filgrastim, trastuzumab, etc.) with FDA/EMA approvals and emerging APAC commercialization. Direct peer via overlapping biosimilar assets and emerging-markets distribution playbook.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SciGen Korea Ltd.

Biopharmaceutical Commercializationscigen.co.kr

SciGen Korea Ltd. is a Seoul-based biopharmaceutical subsidiary of Singapore's SciGen Pte. Ltd. that markets and commercializes brand drugs, generics/biosimilars, and medical devices across 12+ Asia-Pacific and emerging markets, serving healthcare providers and patients in oncology, endocrinology, and supportive care.

What SciGen Korea Ltd. does

SciGen Korea Ltd. is a South Korea-based biopharmaceutical subsidiary of Singapore-incorporated SciGen Pte. Ltd., employing approximately 12 people. The company markets and commercializes an integrated portfolio of healthcare products organized across three segments: Brand Drugs, Generics/Biosimilars, and Medical Devices. Its proprietary assets include Lorelin (the first GnRHa developed in Korea with an international patent), SciXeg (a pegfilgrastim biosimilar approved by both the FDA and EMA), SciLocyte (the first Filgrastim in pre-filled syringe format), SciTropin A (a European-quality recombinant human growth hormone in ready-to-use format), and the LTU-904 low-level laser treatment device for post-mastectomy lymphoedema. The portfolio also extends to in-licensed or distributed products such as Zometa, Diphereline, Gensulin/SciLin, ISCADOR, HERI, Zinc-S, and NeoTrace 4, spanning oncology, endocrinology, hematology, and supportive care.

SciGen operates a sales-led go-to-market built on out-licensing, partner due diligence, market analysis, and distribution agreements with manufacturers and channel partners. Products are commercialized across 12+ Asia-Pacific and emerging markets including South Korea, Philippines, Australia, Singapore, Malaysia, Vietnam, Hong Kong, Thailand, Taiwan, Indonesia, Brunei, and New Zealand. Revenue is generated through pharmaceutical product sales and licensing/distribution arrangements, with quote-based pricing through healthcare providers and distributors rather than disclosed list pricing. The customer base is described as healthcare providers and patients globally, with no named anchor customers or segment-level revenue disclosure.

The company is privately held with no disclosed funding rounds, institutional investors, or public listing. Its operating structure is lean relative to its geographic footprint, with a small team executing commercialization rather than in-house drug discovery. Strategic emphasis is on continuous portfolio fill and improvement across the three product categories, leveraging international regulatory approvals as a primary differentiation lever.

SciGen Korea Ltd. firmographics

Firmographics
Name
SciGen Korea Ltd.
Legal name
SciGen Pte. Ltd.
Website
https://scigen.co.kr
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
SciGen Korea Ltd. is a Seoul-based biopharmaceutical subsidiary of Singapore's SciGen Pte. Ltd. that markets and commercializes brand drugs, generics/biosimilars, and medical devices across 12+ Asia-Pacific and emerging markets, serving healthcare providers and patients in oncology, endocrinology, and supportive care.
Ownership category
akta.pro rank

SciGen Korea Ltd. industry classification

Industry
Product category
Biopharmaceutical Commercialization
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution

Keywords

  • Biopharmaceutical products
  • Generic pharmaceuticals
  • Biosimilars distribution
  • Medical devices marketing
  • Oncology supportive care

Where SciGen Korea Ltd. is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices2 records

Markets served

SciGen Korea Ltd. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: SciGen generates revenue through the marketing and commercialization of innovative healthcare products including brand drugs, generics, biosimilars, and medical devices. The company markets products worldwide across multiple countries including South Korea, Philippines, Australia, Singapore, Malaysia, Vietnam, Hong Kong, Thailand, Taiwan, Indonesia, Brunei, and New Zealand.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

SciGen Korea Ltd. product offering

Product offering

Core offering

SciGen Korea markets and commercializes an integrated biopharmaceutical portfolio across Brand Drugs, Generics/Biosimilars, and Medical Devices for oncology supportive care, endocrinology, hematology, and immunology. The company distributes proprietary products such as Lorelin (GnRHa) and SciXeg (pegfilgrastim biosimilar), along with partnered brands like Zometa, Diphereline, Gensulin, and the LTU-904 laser device, through partner manufacturers and distributors across South Korea and other international markets.

Product overview

SciGen is a biopharmaceutical company that markets and commercializes an integrated portfolio of innovative healthcare products organized across three main segments: Brand Drugs, Generics/Biosimilars, and Medical Devices. The company's product portfolio includes injectable pharmaceuticals (SciXeg® biosimilar, SciLocyte™, HERI®, Zometa®, Diphereline®, SciTropin A™, Gensulin®/SciLin™), oncology supportive care products (ISCADOR®, Zinc-S®, NeoTrace 4®), medical devices (LTU-904 laser treatment, Gensupen 2® insulin delivery device), and hormonal therapies (Lorelin). The products span therapeutic areas including endocrinology, oncology, hematology, and supportive care, with distribution across South Korea, Australia, Southeast Asia, and emerging markets worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • SciXeg: Biosimilar of pegfilgrastim approved by both the FDA and EMA for oncology and hematology supportive care.
  • SciTropin A
  • SciLocyte

Products and services

  • Lorelin Lorelin is the first GnRHa (Gonadotropin-Releasing Hormone agonist) developed in Korea with international patent approval. It is used for endocrinology, oncology, and OBGY indications, currently marketed in South Korea.
  • SciXeg® (pegfilgrastim biosimilar 6mg) SciXeg is a G-CSF (granulocyte colony-stimulating factor) biosimilar of pegfilgrastim supplied as a 6mg pre-filled syringe injection, approved by both the FDA and EMA, and used for oncology and hematology supportive care. Marketed in South Korea.
  • LTU-904 LTU-904 is an innovative low-level laser treatment medical device for patients suffering from Post-Mastectomy Lymphoedema. Marketed in South Korea.
  • Gensupen 2® Gensupen 2 is an insulin delivery medical device used with injectable pharmaceutical products, distributed in emerging markets and used by thousands of patients worldwide.
  • Zinc-S® Zinc-S is a zinc sulfate hydrate pharmaceutical product for the prevention of low zinc levels, used in oncology applications. Marketed in South Korea.
  • NeoTrace 4® NeoTrace 4 is a sterile, nonpyrogenic solution of zinc, copper, manganese, and chromium used to prevent depletion of endogenous trace element stores and subsequent deficiency symptoms. Marketed in South Korea for oncology.
  • ISCADOR® ISCADOR is a Swiss-made mistletoe (Viscum album) extract product addressing oncology support needs. Marketed in South Korea.
  • HERI® HERI is an immune modulator containing Thymosin α1 designed to boost immune defense in immunocompromised patients. Marketed in South Korea.
  • SciLocyte™ (Filgrastim in pre-filled syringe) SciLocyte is the first Filgrastim in pre-filled syringe (PFS) format, a G-CSF product for increasing Absolute Neutrophil Count (ANC) with proven efficacy and safety. Currently marketed in the Philippines.
  • Zometa® (zoledronic acid) Zometa is a ready-to-use zoledronic acid formulation for bone-related conditions, marketed in Australia, Brunei, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.
  • Diphereline® Diphereline is a prolonged-acting GnRH agonist with proven efficacy and safety data since 1986, used in endocrinology applications.
  • SciTropin A™ (recombinant human growth hormone) SciTropin A is a European quality recombinant human growth hormone (rhGH) supplied in a ready-to-use format for short stature correction. Currently marketed in Australia, Philippines, South Korea, Singapore, Vietnam, Malaysia, Hong Kong, and Thailand.
  • Gensulin® / SciLin™ (recombinant human insulin) Gensulin (also marketed as SciLin) is a high-quality European recombinant human insulin with 20 years of experience confirming effectiveness, safety, and stability. Available in multiple formulations including Scilin N, Scilin R, and Scilin M30, distributed in emerging markets.

Companies that use SciGen Korea Ltd.

Customer profile

Segments1 record

Ideal customer profiles2 records

SciGen Korea Ltd. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SciGen Korea Ltd. partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Potential Manufacturers and Distributors (unnamed)coreChannel Partner/ Reseller/ DistributorSciGen partners with manufacturers and distributors across different markets to represent their products. The partnership involves reaching out to potential partners, conducting partner due diligence, market analysis, product finalization, and agreement negotiation and finalization.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

SciGen Korea Ltd. competitors and assessment

Company assessment

Direct peers

  • Celltrion: South Korea's leading biosimilar developer and manufacturer, with FDA/EMA approved pegfilgrastim and filgrastim biosimilars that directly compete with SciXeg and SciLocyte. Directly comparable in product category, regulatory strategy, and APAC commercial reach.
  • Alvotech: Iceland-based pure-play biosimilar developer with FDA/EMA approvals across oncology and immunology, actively expanding APAC distribution partnerships. Comparable as a biosimilar-focused company pursuing multi-territory regulatory commercialization.
  • Samsung Bioepis: Korean biosimilar specialist developing and commercializing multiple oncology and immunology biosimilars with FDA/EMA approvals. Directly comparable as a Korean-headquartered biosimilar player with global regulatory reach.
  • Intas Pharmaceuticals: India-based specialty generics and biosimilar manufacturer with global footprint via Accurex and other channels, active in oncology and immunology biosimilars. Comparable in product mix and multi-territory partner-driven commercialization.
  • Stada Arzneimittel: German specialty generics and biosimilar manufacturer with broad European specialty footprint and growing APAC presence. Comparable as a multi-territory specialty/generics player with in-licensing and partner distribution focus.
  • Biocon Biologics: India-headquartered developer of biosimilars (pegfilgrastim, filgrastim, trastuzumab, etc.) with FDA/EMA approvals and emerging APAC commercialization. Direct peer via overlapping biosimilar assets and emerging-markets distribution playbook.

Broad incumbents

  • Lupin Limited: India-headquartered specialty pharmaceutical company with branded specialty, biosimilars, and complex generics across global markets including APAC and emerging regions. Comparable via specialty pharma breadth and partner distribution emphasis.
  • Dr. Reddy's Laboratories: India's largest specialty pharmaceutical company with proprietary products, biosimilars (including G-CSF franchise), and significant APAC and emerging-markets presence. Comparable via biosimilar G-CSF overlap and broad specialty pharma portfolio.
  • Cipla: India-based global pharmaceutical company with deep presence in oncology, respiratory, and specialty segments across APAC and emerging markets, including biosimilar and branded specialty franchises. Comparable as a large incumbent with overlapping therapeutic-area breadth and emerging-markets focus.
  • LG Chem Life Sciences: Korean diversified chemical and life sciences business with growing specialty pharma and biosimilar investments, including growth hormone and oncology supportive care franchises. Comparable as a Korean specialty player expanding APAC and global biosimilar franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

SciGen Korea Ltd. social profiles

Digital presence

SciGen Korea Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SciGen Korea Ltd. leadership team

Management profile

Number of profiles

Profiles1 record

SciGen Korea Ltd. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SciGen Korea Ltd. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SciGen Korea Ltd.

What does SciGen Korea Ltd. do?

SciGen Korea markets and commercializes an integrated biopharmaceutical portfolio across Brand Drugs, Generics/Biosimilars, and Medical Devices for oncology supportive care, endocrinology, hematology, and immunology. The company distributes proprietary products such as Lorelin (GnRHa) and SciXeg (pegfilgrastim biosimilar), along with partnered brands like Zometa, Diphereline, Gensulin, and the LTU-904 laser device, through partner manufacturers and distributors across South Korea and other international markets.

Is SciGen Korea Ltd. a public or private company?

SciGen Korea Ltd. is a private company. It is classified as unknown and is currently operating.

When was SciGen Korea Ltd. founded?

SciGen Korea Ltd. was founded in -1. It employs 11 to 50 people.

Where is SciGen Korea Ltd. based?

SciGen Korea Ltd. is headquartered in Singapore, Singapore, in the Asia region.

How does SciGen Korea Ltd. make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are SciGen Korea Ltd.'s main competitors?

Direct peers on record are Celltrion, Alvotech, Samsung Bioepis, Intas Pharmaceuticals, Stada Arzneimittel and Biocon Biologics. Broad incumbents are Lupin Limited, Dr. Reddy's Laboratories, Cipla and LG Chem Life Sciences.

Does SciGen Korea Ltd. have an API?

No public API is recorded for SciGen Korea Ltd..

What industry is SciGen Korea Ltd. in?

SciGen Korea Ltd.'s product category is Biopharmaceutical Commercialization. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales